Business judgment on AI products
Researchers doing early drug discovery open it when choosing ADMET, kinase or toxicity prediction models: it runs several prediction tools against one shared benchmark, so the user gets a side-by-side evaluation to decide which model to adopt. Which datasets are covered, how metrics are defined and whether it is updated continuously are not stated publicly and still need checking.
01
Start inside the user's day · Public facts + workflow reasoning · 2026-10-12
A drug discovery team choosing ADMET, kinase or toxicity prediction models needs a comparable evaluation to decide which tool to adopt.
Comparing papers, running small in-house reproductions, or defaulting to the model the team already knows.
Reported metrics differ across papers, reproduction is costly, and selection often rests on impressions or a single paper.
Trend: vertical research fields are getting independent third-party evaluation layers, so model choice shifts from reading papers to reading a shared leaderboard. Wedge: enter at the model-selection step inside pharma companies or CROs and sell evaluation and reproduction services rather than models; the maintainer, funding and commercial path are not disclosed, so this is inference.
Inference: if it scores multiple tools on one benchmark, it removes the step of building an evaluation harness, so R&D teams that must justify model choices would consult it first; but the public material is one line with no maintainer, update cadence or user feedback, so sustained adoption cannot be confirmed.
An English validation note will follow from the public evidence.
Keep watching. Inference: if it scores multiple tools on one benchmark, it removes the step of building an evaluation harness, so R&D teams that must justify model choices would consult it first; but the public material is one line with no maintainer, update cadence or user feedback, so sustained adoption cannot be confirmed.
Trend: vertical research fields are getting independent third-party evaluation layers, so model choice shifts from reading papers to reading a shared leaderboard. Wedge: enter at the model-selection step inside pharma companies or CROs and sell evaluation and reproduction services rather than models; the maintainer, funding and commercial path are not disclosed, so this is inference.
Researchers doing early drug discovery open it when choosing ADMET, kinase or toxicity prediction models: it runs several prediction tools against one shared benchmark, so the user gets a side-by-side evaluation to decide which model to adopt. Which datasets are covered, how metrics are defined and whether it is updated continuously are not stated publicly and still need checking.
Inference: if it scores multiple tools on one benchmark, it removes the step of building an evaluation harness, so R&D teams that must justify model choices would consult it first; but the public material is one line with no maintainer, update cadence or user feedback, so sustained adoption cannot be confirmed.
An English validation note will follow from the public evidence.
The product claims to help users complete: “Researchers doing early drug discovery open it when choosing ADMET, kinase or toxicity prediction mo”. User evidence has not yet verified pain intensity or the cost of doing without it.
The assessment is recorded; an English explanation is pending.
The assessment is recorded; an English explanation is pending.
The assessment is recorded; an English explanation is pending.
02
Market comparison
The Chinese–English market comparison is not complete yet. A conclusion follows only after its coverage and verifiable evidence are recorded.
There is no full analysis yet. Start with the direction above.
Public information is limited; this view will update as more evidence appears. It was recently added and does not yet have verifiable usage data.
Full analyses of similar products: deepseek-harness, open-kimi-ppt-skill
05
Use these searches when the official site is missing or the current link is only a lead.